“TWST: Now you are the only manufacturer in the world of Cesium-131 brachytherapy seeds. Is there any competition on the horizon?
Mr. LaVoy: IsoRay is not aware of any competition on the near term horizon for Cesium-131. Cesium-131 was the last developed low-dose rate — LDR — isotope for the treatment of cancer through brachytherapy. IsoRay holds several patents related to purification of Cesium-131 and also a seed construction patent and a number of other support patents to protect the propriety of our intellectual property. In terms of competition, there is a high barrier to entry because of the significant amount of time that would be required for someone to develop a process patent, a seed patent as well as get a radiation facility licensed and in place.
The other factor is the market. The prostate brachytherapy market has been disrupted over the past 10 years by robotic surgery and better external beam technologies. I do not believe large companies view the brachytherapy market as a big market opportunity. It is considered a niche market and also considered disrupted, so we do not see any large competitors in the short or midterm trying to come in and produce Cesium-131. We see this as our opportunity over the next three to four years.
Our growth strategy includes our dual goals of continuing to gain acceptance for Cesium-131 in existing markets and also to be first to market with our new applications before any major players recognize the need and opportunity for the product.”
For a free report and the other top investment highlights from the in depth interview with Thomas LaVoy, the Chairman and CEO: IsoRay, Inc. (NYSEMKT:ISR), visit TWST.com.
# # #
NOTE TO INVESTORS AND FINANCIAL NEWS EDITORS: Thomas LaVoy, the Chairman and CEO: IsoRay, Inc. (NYSEMKT:ISR) is available for interviews. Contact Isoray at https://isoray.com/about/management-team/
– See more at https://www.twst.com/report/medical-devices-10/